<DOC>
	<DOC>NCT00168051</DOC>
	<brief_summary>The purpose of the study is to compare the pharmacokinetic parameters of ReFacto and Advate, using the chromogenetic substrate assay to measure plasma Factor VIII activity in plasma.</brief_summary>
	<brief_title>Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe hemophilia A Previously treated patients with at least 150 exposure days to any Factor VIII product Hypersensitivity to any recombinant Factor VIII product History of or current Factor VIII inhibitor Bleeding episode or other reason requiring Factor VIII treatment within 3 days of study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Hemophilia A</keyword>
</DOC>